Palopegteriparatide API is a long-acting parathyroid hormone receptor agonist (PTH1R agonist) engineered for therapeutic applications in regulating calcium balance.

It is specifically developed for the treatment of chronic hypoparathyroidism.

It is designed to provide sustained physiological levels with a once-weekly dosing schedule.

It acts as a pegylated analog of PTH (1-34) that binds to PTH1 receptors to restore calcium and phosphate homeostasis.

It works by increasing serum calcium concentration while simultaneously decreasing urinary calcium excretion.

Palopegteriparatide supports ongoing bone metabolism and overall mineral homeostasis in the body.